Výsledky vyhledávání - "Julio A Peguero"

Abstract PD1-07: A Phase 2 study of poziotinib in patients with HER2-positive metastatic breast cancer heavily pre-treated with HER2-targeted therapy

Autor: Malik Zulfiqar, Kate Lathrop, Francois Lebel, Adam Brufsky, Gajanan Bhat, Julio Antonio Peguero

Publikováno v: Cancer Research. 81:PD1-07

Background: Poziotinib is a novel pan-HER inhibitor that irreversibly blocks the EGFR family of tyrosine-kinase receptors and inhibits the proliferation of tumor cells. This study evaluates the safety and clinical activity of poziotinib in patients w

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e4b5ae6546d0bd0c490ecd4135cb8200
https://doi.org/10.1158/1538-7445.sabcs20-pd1-07

Zobrazit plný text záznamu

Eflapegrastim, a Long-Acting Granulocyte-Colony Stimulating Factor for the Management of Chemotherapy-Induced Neutropenia: Results of a Phase III Trial

Autor: Inderjit Mehmi, Gajanan Bhat, Julio Antonio Peguero, Lee S. Schwartzberg, Zane Yang, Patrick Wayne Cobb, Shanta Chawla, Jayaram S. Bharadwaj, Osama Hlalah, Steven J. Hasal, Richy Agajanian, Alvaro Restrepo

Publikováno v: The Oncologist

Background Eflapegrastim, a novel, long‐acting recombinant human granulocyte‐colony stimulating factor (rhG‐CSF), consists of a rhG‐CSF analog conjugated to a human IgG4 Fc fragment via a short polyethylene glycol linker. Preclinical and phas

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::40b0adae00c07af96a627a67b7b73197
https://doi.org/10.1634/theoncologist.2020-0105

Zobrazit plný text záznamu

Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research, vol 26, iss 6
Clin Cancer Res

Purpose: Bromodomain and extraterminal (BET) proteins are key epigenetic transcriptional regulators, inhibition of which may suppress oncogene expression. We report results from 2 independent first-in-human phase 1/2 dose–escalation and expansion,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50020508bf4925094286db6a47e8069d
https://doi.org/10.1158/1078-0432.ccr-18-4071

Zobrazit plný text záznamu

Abstract P2-14-12: Eflapegrastim, a novel long-acting granulocyte-colony stimulating factor: Integrated safety results in patients with early-stage breast cancer treated with TC chemotherapy

Autor: Jayaram S. Bharadwaj, Julio Antonio Peguero, Inderjit Mehmi, Patrick Wayne Cobb, Francois Lebel, Shanta Chawla, Gajanan Bhat, Richy Agajanian, Lee S. Schwartzberg, Alvaro Restrepo, Osama Hlalah

Publikováno v: Cancer Research. 80:P2-14

Background: Eflapegrastim (E) represents the first myeloid growth factor innovation in more than 15 years. A novel, long-acting recombinant human granulocyte-colony stimulating factor (rhG-CSF), E consists of a rhG-CSF analog conjugated to a human Ig

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::95060e174c3f6de425c62173cefa24a9
https://doi.org/10.1158/1538-7445.sabcs19-p2-14-12

Zobrazit plný text záznamu

Tissue/Site-Agnostic Study of Ribociclib for Tumors With Cyclin D-CDK4/6 Pathway Genomic Alterations: A Phase II, Open-Label, Single-Arm Basket Study

Autor: Karen Kelly, Lincoln Nadauld, Vivek Subbiah, Davendra Sohal, Howard Safran, Julio Antonio Peguero, Alejandro D. Ricart, Erica Stealey, Juneko E. Grilley-Olson, Das Purkayastha, Joseph Paul Eder, Bert H. O'Neil, Barinder P. Kang

Publikováno v: JCO precision oncology. 3

PURPOSE As part of the Novartis Signature Program, this study evaluated the efficacy of ribociclib (selective cyclin-dependent kinase 4/6 [CDK4/6] inhibitor) in patients with cyclin D–CDK4/6 pathway–aberrant tumors. METHODS This was a phase II, s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25f7aeae9699bf59c9b2753a2c6e2410
https://pubmed.ncbi.nlm.nih.gov/35100715

Zobrazit plný text záznamu

Intravenous Cetirizine vs Intravenous Diphenhydramine for the Prevention of Hypersensitivity Infusion Reactions: Results of an Exploratory Phase 2 Study

Autor: Jarrod P. Holmes, Nancy Joseph-Ridge, Lonnie D. Brent, Janine North, Julio A. Peguero, R. Campbell Garland, Stacia Young

Publikováno v: Journal of Infusion Nursing

Pretreatment with antihistamines for the prevention of hypersensitivity infusion reactions is recommended for certain biologics and chemotherapies. Cetirizine is the first injectable second-generation antihistamine recently approved for acute urticar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29f3fd0fb2f5fbd2fdef7eb26b913e8f
https://pubmed.ncbi.nlm.nih.gov/34555839

Zobrazit plný text záznamu

TACTI-003: A randomized phase IIb study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab as first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma

Autor: Douglas Adkins, Valerii Cheshuk, Julio Antonio Peguero, John J. Park, Antonio Lopez-Pousa, Willem Lybaert, Irene Brana, Bernard Doger, Frederic Triebel

Publikováno v: Journal of Clinical Oncology. 40:TPS6099-TPS6099

TPS6099 Background: Eftilagimod alpha (efti) is a soluble LAG-3 protein targeting a subset of MHC class II molecules that mediate antigen presenting cell (APC) and CD8 T-cell activation. Data from a non-randomized, phase II trial of efti plus pembrol

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8c2475e9733bea739788e94c1b1a92f6
https://doi.org/10.1200/jco.2022.40.16_suppl.tps6099

Zobrazit plný text záznamu

Operational metrics for the ELAINE II study combining a traditional approach with a just-in-time model

Autor: Sibel Blau, Julio Antonio Peguero, Halle C. F. Moore, Ian Churchill Anderson, Minal A. Barve, Mathew Amprayil Cherian, Ahmed Elkhanany, Ciara Catherine Maria O'Sullivan, Alvaro Moreno-Aspitia, Paul Plourde, Lyon L. Gleich, Kendra Riesen, Ross Ezzati, Meghan Degele, Megan Shulman, Stephanie Stempf, Matthew M. Cooney, Senthil Damodaran

Publikováno v: Journal of Clinical Oncology. 40:1504-1504

1504 Background: Trial recruitment that requires specific actionable mutations based on next-generation sequencing (NGS) is challenging. Barriers can include competing studies, physician study awareness, site proximity, mutation incidence, among othe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::36d445d64791bade7c20064e6f494507
https://doi.org/10.1200/jco.2022.40.16_suppl.1504

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání